ProMetic Life Sciences
|Founded||October 14, 1994|
|Headquarters||440 Boul. Armand-Frappier Suite 300, Laval, Québec, Canada|
Prometic was founded in 1988, as a commercial spinoff of research at the University of Cambridge on affinity chromatography. Its founder was the current President and CEO, Pierre Laurin, whose research formed the basis for the company's products. On May 19, 1998,the Corporation went public through a listing on the Toronto Stock Exchange.
Most of the company's products are based on its affinity chromatography process. One use of this process is the purification of drugs, reducing impurities and thus side effects. A second use is removing pathogens from human blood; in 2002, ProMetic formed a joint venture with the American Red Cross to remove pathogens and viruses from collected blood. A third application is to extract and purify therapeutic proteins from human plasma, which are then used in the creation of therapeutics and orphan drugs.
Prometic has two business segments: the protein technologies segment and the small-molecule therapeutics segment.
Headquartered in Laval, Quebec, Prometic has:
- Research and development facilities in the UK, the US and Canada
- Manufacturing facilities in the UK and Canada
It also conducts business development activities in the US, Europe and Asia. As of 2015, it has approximately 250 employees.
- "Most Innovative CEO of the Year: Pierre Laurin, Prometic". Canadian Business - Your Source For Business News. 2015-10-19. Retrieved 2018-04-20.
- "ProMetic to Acquire Telesta Therapeutics - GEN". GEN.
- "ProMetic to team with Red Cross". The Globe and Mail. 2002-04-22. Retrieved 2018-04-20.
- "Three top stock picks from Selective Asset's Robert McWhirter". The Globe and Mail. 2014-08-29. Retrieved 2018-04-20.
- "Today's Stock Market News and Analysis from Nasdaq.com". NASDAQ.com.